SCHEMBL14228248

SCHEMBL14228248

CCc1cccc(NC(=O)c2cccc(OCc3ccccc3)c2NC)c1

nearest known ligand 0.64

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 4/20 0.64
▸ KMT2A Q03164 4/20 0.64
▸ SGMS2 Q8NHU3 2/20 0.60
▸ GAA P10253 1/20 0.54
▸ LRRK2 Q5S007 5/20 0.53
▸ ALDH1A1 P00352 1/20 0.51
▸ TAS1R3 Q7RTX0 1/20 0.50
▸ TAS1R1 Q7RTX1 1/20 0.50
▸ TAS1R2 Q8TE23 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ PARP1 P09874 2/20 0.49
▸ PARP2 Q9UGN5 2/20 0.49
▸ KCNK3 O14649 1/20 0.49
▸ KCNK9 Q9NPC2 1/20 0.49
▸ SENP5 Q96HI0 1/20 0.48
▸ SENP2 Q9HC62 1/20 0.48
▸ SENP1 Q9P0U3 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14199819 0.88 MEN1 (0.60) MEN1KMT2ASGMS2GAALRRK2
SCHEMBL4941693 0.82 MEN1 (0.63) MEN1KMT2ASGMS2LRRK2SMN1; SMN2
SCHEMBL10323195 0.80 LRRK2 (0.80) MEN1KMT2ASGMS2LRRK2PARP1
SCHEMBL19049633 0.77 SMN1; SMN2 (0.61) MEN1KMT2ASGMS2GAALRRK2
SCHEMBL1648383 0.77 MEN1 (1.00) MEN1KMT2ASGMS2GAALRRK2
SCHEMBL875474 0.76 SGMS2 (1.00) MEN1KMT2ASGMS2GAAALDH1A1
SCHEMBL1650152 0.75 LRRK2 (0.77) MEN1KMT2ASGMS2GAALRRK2
SCHEMBL24934209 0.73 F2R (0.67) MEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL23367850 0.73 MEN1 (0.62) MEN1KMT2AALDH1A1TAS1R3TAS1R1
SCHEMBL11779160 0.73 KMT2A (0.63) MEN1KMT2ASGMS2LRRK2KCNK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778874-B2 Glycopeptide antibiotic monomer derivatives NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2014-07-15 — — US disclosed
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria SHIONOGI & CO., LTD. (JP) 2008-04-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria CSGALNACT1, MON2, NR2C2 MEN1 4301/4885KMT2A 2424/4885SGMS2 1598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback